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Abstract
CTEN/TNS4 is an oncogene in colorectal cancer (CRC) which enhances cell motility although the mechanism of Cten
regulation is unknown. We found an association between high Cten expression and KRAS/BRAF mutation in a series of CRC
cell lines (p=0.03) and hypothesised that Kras may regulate Cten. To test this, Kras was knocked-down (using small
interfering (si)RNA) in CRC cell lines SW620 and DLD1 (high Cten expressors and mutant for KRAS). In each cell line, Kras
knockdown was mirrored by down-regulation of Cten Since Kras signals through Braf, we tested the effect of Kras
knockdown in CRC cell line Colo205 (which shows high Cten expression and is mutant for BRAF but wild type for KRAS). Cten
levels were unaffected by Kras knockdown whilst Braf knockdown resulted in reduced Cten expression suggesting that Kras
signals via Braf to regulate Cten. Quantification of Cten mRNA and protein analysis following proteasome inhibition
suggested that regulation was of Cten transcription. Kras knockdown inhibited cell motility. To test whether this could be
mediated through Cten, SW620 cells were co-transfected with Kras specific siRNAs and a Cten expression vector. Restoring
Cten expression was able to restore cell motility despite Kras knockdown (transwell migration and wounding assay,
p,0.001 for both). Since KRAS is mutated in many cancers, we investigated whether this relationship could be
demonstrated in other tumour models. The experiments were repeated in the pancreatic cancer cell lines Colo357 & PSN-
1(both high Cten expressors and mutant for KRAS). In both cell lines, Kras was shown to regulate Cten and forced expression
of Cten was able to rescue loss of cell motility following Kras knockdown in PSN-1 (transwell migration assay, p,0.001). We
conclude that, in the colon and pancreas, Cten is a downstream target of Kras and may be a mechanism through which Kras
regulates of cell motility.
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Introduction
C-terminal tensin-like (Cten, TNS4) is a member of the Tensin
gene family. This gene family comprises four members (TNS1,
TNS2, TNS3 and TNS4/CTEN) and their products are localised to
the cytoplasmic tails of integrins at focal adhesions. Tensins play
an important role in various biological processes such as cell
adhesion, migration, proliferation, differentiation, apoptosis and
invasion [1,2,3]. Human tensins 1, 2 and 3 are highly homologous
at their N- and C-termini, but tensin4 / COOH-terminus Tensin-
like molecule (Cten) is a smaller protein which shows C-terminus
homology but does not contain the N-terminus actin-binding
domain that is present in the other tensin proteins [4].
The role of Cten in neoplasia is complex. Mutations have not
beendescribed and changes in wild type Cten expression seem to be
context dependent – it is down-regulated in prostate cancer [4] and
is therefore thought to act as a tumour suppressor. In contrast , it is
up-regulated and therefore acts as an oncogene in many cancers
including breast cancer and colorectal cancer (CRC) [5,6,7]. We
have recently shown that high levels of Cten expression are
associated with a poor prognosis in breast cancer [8] and similar
results have been reported in thymomas, gastric cancers and lung
cancers [9,10,11]. The impact of Cten expression on clinical
outcome may be related to its biological activity which, in colorectal
cancer cell lines at least, results in enhanced colony formation,
resistance to staurosporine-induced apoptotic stress and increased
cell motility (both cell migration and cell invasion) [5,7].
Tensin family proteins interact with several structural and
signalling molecules such as vinculin, paxillin, Src, Focal Adhesion
Kinase (FAK), phosphatidylinositol-3-kinase (PI3-K), and Crk-
associated substrate p130
CAS, actin as well as integrins. Since Cten
is a recently described gene, data about either its regulation or its
downstream targets are sparse. In breast cancer, Cten is positively
regulated by c-Erb-B2 protein [6] – this is over-expressed in a
specific subset of breast cancers due to gene amplification and is a
part of the Epidermal Growth Factor Receptor (EGFR) signalling
pathway. The EGFR pathway signals through Kras/Braf and
although EGFR/c-Erb-B2 amplifications are rare in CRC, gain-
of-function mutations in KRAS/BRAF are extremely common and
are seen in up to 60% of tumours [12,13]. We have previously
studied a series of CRC cell lines for both expression of Cten and
somatic mutation in a several known oncogenes / tumour
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significant association between high Cten expression and KRAS/
BRAF mutation (p=0.03, Table 1 and Table S1). This led us to
hypothesise that Cten is a target of Kras/Braf signalling and in this
study we sought to test this hypothesis and thereby elucidate the
mechanisms of Cten regulation. We tested our hypothesis in CRC
cell lines and then validated the findings in pancreatic cancer cell
lines. The latter were chosen to represent a different type of cancer
which also has a high frequency of KRAS mutation.
Materials and Methods
Tissue culture
The CRC cell lines used in this study (SW620, DLD-1, Colo
205, RKO) were kindly donated by Prof I Tomlinson and have
been previously described [5,13]. The pancreatic cell lines,
Colo357 and PSN-1 are well described cell lines [14,15] which
both contain mutant KRAS. All cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen)
supplemented with 10% fetal calf serum (Invitrogen) and 1%
penicillin/streptomycin (Invitrogen) in 5% CO2 in a humidified
atmosphere.
Transfection of cell lines and proteasomal inhibition
In order to knock down Cten, Braf and Kras, cells were
transfected with small interfering RNA (siRNA) duplexes using
Lipofectamine 2000 (Invitrogen) as previously described [16]. The
cells were transfected with each siRNA duplex at a final
concentration of 100 nM and compared with cells transfected with
sequence scrambled control (ssc) duplexes (i.e. duplexes with the
same base composition arranged in a random order). Two different
duplexes were used for Kras knockdown and the sequences of the
gene-specific duplexes and scrambled controls are as follows:
(1) Kras specific 59CAGGGUGUUGAUGAUGCCUUCUAUA93
and scrambled control 59CAGUGUAGUAGUCGUUUCUCG-
GAUA93 (2) Kras specific 59UAUAGAAGGCAUCAUCAACA-
CCCUG93 and scrambled control 59UAUCCGAGAAACGA-
CUACUACACUG93.
In order to induce Cten expression, cells were transfected with a
CMV promoter driven expression construct containing Green
Fluorescent Protein (GFP) tagged Cten (GFP-Cten) using Lipo-
fectamine 2000 (Invitrogen) as previously described [5]. Control
cells were transfected with a GFP empty vector. In order to inhibit
Wnt signalling, cells were transfected with an expression vector
containing dominant negative (DN) TCF4 as previously described
[17].
In order to functionally evaluate the functional relationship
between Kras and Cten, a specific cellular condition was created
whereby Kras protein was depleted and Cten protein was restored.
This was achieved by co-transfection of Kras-specific siRNA and
GFP-Cten and, for this purpose, the protocol for siRNA
transfection was used with appropriate amounts of plasmid mixed
in with the siRNA prior to adding to Lipofectamine 2000. Cells
were analysed 72 hours later by Western blot or functional assays.
In order to ascertain the role of proteasomal degradation in the
Kras mediated regulation of Cten, the proteasomal inhibitor Z-
Leu-Leu-Phe-CHO, (Sigma , USA), was added to SW620 cells
24 hours after transfection with siRNA duplexes (either Kras
specific or scrambled control).
RNA extraction and Quantitative RT-PCR (Q-RT-PCR)
Total RNA was extracted from cells using the RNeasy Mini Kit
(Qiagen) following the manufacturer’s protocols and quantified on
a NanoDrop ND-1000 UV-Vis Spectrophotometer (LabTech
International Ltd, Ringmer, UK as previously described [16].
Complementary DNA (cDNA) was synthesized using M-MLV
reverse transcriptase (Invitrogen) in accordance with the manu-
facturer’s instructions.
Quantification of Cten and Kras was performed using the
standard curve method. All experiments were conducted in
triplicate and test gene values were normalized to the housekeep-
ing gene HPRT. Each PCR was of a final volume of 25 ml and
contained 10 ng of cDNA template, 16SYBR Green Master Mix
(Stratagene) and 250 nM primers. PCR was performed on an
MX3005P Real-time PCR machine (Stratagene, UK) and cycling
conditions were 5 minutes denaturation at 95uC followed by 40
cycles of: 30 seconds denaturation at 95uC/30 seconds annealing
[60uC for Cten/59uC for HPRT/50uC for Kras/30 seconds
extension at 72uC and a single final extension for 10 minutes.
The data for Q-PCR were analyzed using the MxPro-QPCR
software for Mx3005P QPCR system. PCR primer sequences are
available from the authors.
Western blotting
Whole cell extracts were prepared using lysis buffer (20 mM
Tris, pH 7.5, 150 mM NaCl, 1% TritonX-100, 0.5% sodium
deoxycholate, 1 mM EDTA, 0.1% SDS, supplemented with
protease and phosphatase inhibitors (Sigma)). 30 mg protein was
loaded on a 10% SDS–PAGE gel and transferred onto PVDF
membranes by semi-dry transfer. After blocking, membranes were
incubated overnight at room temperature with the indicated
primary antibody. Antibodies were used at the following dilution:
anti-Cten (Sigma, WH0084951M1, 1:1000), anti-E-Cadherin
(Abcam, ab1416, 1:1000), mouse anti-Kras (Abcam, ab16795,
1:250), mouse anti-b-actin (Sigma, 1:2000) and mouse anti-CD24
(SWA11 – supernatant specific for an N-terminal epitope, a kind
gift from Prof Altevogt). After three washes in TBS/Tween-20
(0.05%), blots were incubated for 1 hour at room temperature
with the appropriate horseradish peroxidase-linked secondary
antibody. After three further washes, detection was performed
using the Enhanced Chemiluminescence Kit (Pierce). Bands were
visualised using X-Ray films (Kodak) and quantified using ImageJ
software.
Flow cytometry
In order to test the transfection efficiency of GFP-Cten into
SW620, cells were initially transfected with GFP-CTEN as above.
After 48 hours, the cells were non-enzymatically detached by
incubating with TE buffer (10 mM Tris-HCl (pH 8), 1 mM
EDTA, Sigma) for 5–10 minutes. These then underwent anlaysis
in an Epics Altra Flow cytometer (Beckman Coulter). 600,000
events were analysed using a GFP filter with the appropriate gate
parameter.
Table 1. Association of Cten expression Kras/Braf mutation.
Kras/Braf status of cell line
Mutant Wild Type
Low Cten expression 46
High Cten expression 15 3
A series of cell lines had previously been analysed for Cten expression and Kras/
Braf mutation. Analysis of the data showed a significant association between
up-regulation of Cten expression (i.e. greater than normal mucosa) and
mutation in any of the Kras/Braf hotspots (Fisher’s exact test, p=0.03).
doi:10.1371/journal.pone.0020919.t001
Cten and Kras
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20919Confirmation of the efficacy of the DN-TCF expression vector
was tested by the effect on CD24 expression (a well known Wnt
target gene) [18,19]. Forty eight hours after transfection with the
DN-TCF construct, cells were non-enzymatically detached and
approximately 5610
5 cells were incubated with PE-labelled anti-
CD24 antibody (BD Biosciences) diluted 1:100 in FACS wash
(0.5% bovine serum albumin; 2 mM NaN3; 5 mM EDTA) for
15 minutes at 4uC. An isotype and concentration matched PE
labelled control antibody (Miltenyi Biotec, UK) was used and
samples labelled with this antibody were used to set the gating
levels. After three 5 minute washes with FACS wash, the cells were
re-suspended and fixed in solution containing FACS wash with
2% formaldehyde. Determination of percentage of CD24+ cells
was performed on an Epics Altra flow cytometry machine
(Beckman Coulter). The results were analyzed using WinMDi
2.9 computer software.
Cell Migration/ Invasion Assays
Transwell cell migration was measured using a Boyden
chamber containing a polycarbonate filter with an 8 mm pore
size (Costar). Five 610
4 cells were seeded and cell migration was
assessed after 48 hr by fixing the cells attached to the lower surface
in 10% methanol for 30 minutes. These were then stained for
30 minutes with methylene blue and the stained cells manually
counted. Cell invasion was measured in the same way as described
for migration, except that prior to cell seeding the upper chamber
was prepared by coating the filter with 100 ml Matrigel (5 mg/ml;
BD Biosciences) and the cells attached to the lower surface were
fixed, stained and counted. Cell wounding migration assays were
performed in six-well plates. Cells were grown to confluence and
then serum-deprived for 24 hrs. A sterile 200 ml pipette tip was
used to create three separate parallel wounds and migration of the
cells across the wound line was assessed at 0, 24, 48 and 72 hr.
Photographs were taken using a charge-coupled device (CCD)
camera (Canon, Japan) attached to the inverted phase-contrast
microscope at a power of 406. In order to statistically analyse cell
migration in the wounding assay, images were taken from three
separate wounds All images were taken at the same magnification
and converted into binary images using the ImageJ image analysis
program (http://rsb. info. nih. gov/ij/index. html) and the area of
the wound was measured. All assays were performed in triplicate
on at least two separate occasions.
Statistical analysis
Statistical analysis was undertaken using SPSS 13. 0 Software.
All evaluations were done using unpaired two tailed Student’s T-
test. For cell counting studies cell numbers (as quantified by the
methylene blue assay) were analysed. For the cell wounding
studies, total pixel numbers with an intensity value of 0 were
analysed as previously described [5]. A two-tailed p-value of
,0.05 was considered statistically significant.
Results
(a) Cten and cell motility
We have previously shown that forced expression of Cten
induces cell motility in cell lines not expressing Cten [5]. In order
to validate these data, we conducted the reverse experiment of
Cten knockdown in SW620. This is a CRC cell line showing high
Cten expression (Figure 1a). The knockdown of Cten was also
associated with up-regulation of E-cadherin (Figure 1b) thereby
validating our previous observation of E-caderin down-regulation
following ectopic expression of Cten. SW620 cells transfected with
Cten specific siRNAs showed a reduction in transwell migration
and transwell invasion through matrigel (p,0.001 for both,
Figure 1c and d) when compared with cells transfected with
scrambled controls. Similarly, wound healing assays showed
delayed closure of wound following Cten knockdown (p,0.001,
Figure 1e).
(b) Kras and Cten expression
Having found an association between Cten expression and
KRAS/BRAF mutation in a series of CRC cell lines (Table 1), we
sought to examine whether these were functionally linked. Firstly,
Kras was knocked down in SW620. This cell line contains a KRAS
mutation and is a high expressor of Cten. Knockdown of Kras in
SW620 (annotated as SW620
Kras-) resulted in down-regulation of
Cten (Figure 2a) when compared with scrambled controls
(SW620
ssc). This effect was validated in the cell line DLD1 which
also contains a KRAS mutation and is a high expressor of Cten
(DLD1
Kras- versus DLD1
ssc) both of which produced Kras
knockdown and both of which resulted in down-regulation of
Cten.
Kras signals through Braf and, in order to further test the
association between Kras and Cten, Kras was knocked down in
the cell line Colo205 (containing a mutation in BRAF but wild type
for KRAS). In this case the level of Cten was unaffected
(Colo205
Kras- versus Colo205
ssc, Figure 2b). However when Braf
was knocked down in Colo205, a 52% reduction in Braf protein
(as evaluated by densitometry) was mirrored by a 50% reduction
in Cten expression (Colo205
Braf- versus Colo205
ssc, Figure 2c)
suggesting that Kras influences Cten through Braf.
Since there is early up-regulation of Cten i.e. during the
adenomatous phase of tumour development, the possibility that it
may be a target of Wnt signalling was tested. CD24 is a well
described target of Wnt signalling [18,19] and dominant-negative
TCF4 was transfected into SW620. Quantitative Western blot
demonstrated a 40% reduction in the expression of CD24 and
53% reduction in cells expressing CD24 by flow cytometry (Figure
S1). However transfection of DN-TCF4 into SW620 did not
influence Cten expression (Figure 2d) suggesting that Wnt
signalling does not play a role in regulating Cten expression.
(c) Kras regulates Cten transcription
Our data showed that Cten is regulated, in part at least, by
Kras/Braf signalling although it was uncertain whether this occurs
through direct up-regulation of transcripton or through inhibition
of degradation. In order to test this, Cten mRNA levels were
measured by quantitative RT-PCR following Kras knockdown.
This showed that there was a 43% reduction in normalised Cten
mRNA levels (Figure 3a) suggesting there was transcriptional
regulation. To further validate this, cells were exposed to a
proteasomal inhibitor following Kras knockdown. This would be
expected to prevent protein degradation but it did not prevent
reduction in the levels of Cten (Figure 3b, Figure S2) thus
supporting the quantitative PCR results which suggested that
Kras/Braf signalling alters the transcription of Cten to regulate
Cten protein levels.
(d) Functional interaction between Kras and Cten
Kras was shown to positively regulate Cten but, since Kras has
several hundred downstream targets, it is possible that this is a
reproducible observation without any direct functional relevance to
cell biology. In order to test whether this relationship had any
functional effect, we compared the conditions of Kras knockdown
with Kras knockdown and concomitant ectopically expressed Cten
protein. SW620 cells were thus co-transfected with Kras-specific
siRNA duplexes and a construct causing ectopic expression of
Cten and Kras
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20919Figure 1. Cten stimulates cell motility and alters E-cadherin levels. (a) We have previously shown that forced expression of Cten induces cell
motility. In the reverse experiment, we knocked down Cten protein expression with Cten specific siRNAs (SW620
Cten-) compared with scrambled
controls (SW620
ssc). (b) Knockdown of Cten was associated with up-regulation of E-cadherin. (c) Functionally, knockdown of Cten caused reduction in
transwell migration (upper panel, p,0.001) and transwell invasion through matrigel (lower panel, p,0.001). (d) Wound healing assays shown
delayed closure of wound following Cten knockdown (p,0.001). Upper panel shows wound at time 0 hours and lower panel shows the same field
after 72 hours.
doi:10.1371/journal.pone.0020919.g001
Cten and Kras
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20919Figure 2. Functional relationship between Kras and Cten. (a) Knockdown of Kras in SW620 and DLD1 (both mutant for KRAS) resulted in a
down-regulation of Cten levels (SW620
Kras- versus SW620
ssc-, DLD1
Kras- versus DLD1
ssc-). In contrast, (b) shows that Kras knockdown in Colo205
(containing a BRAF V600E mutation) had no effect on Cten expression (Colo205
Kras- versus Colo205
ssc) whilst (c) shows that knockdown of Braf in
Colo205 did cause down-regulation of Cten (Colo205
Braf- versus Colo205
ssc). Figure (d) shows that inhibition of Wnt signalling in SW620 with a
dominant-negative TCF4 expression vector (SW620
DN-TCF4) did not alter Cten levels compared with empty vector (SW620
evc) whilst levels of CD24 (a
known target of Wnt signalling) were reduced.
doi:10.1371/journal.pone.0020919.g002
Figure 3. Kras regulates Cten through transcriptional control. (a) Following Kras knockdown in SW620, mRNA levels of both Kras and Cten
were quantified and normalised to the housekeeping gene HPRT. There was a reduction in the level of both mRNAs (data shown from three
replicates). (b) To further support this, cells were exposed to a proteasome inhibitor and levels of Kras and Cten proteins quantified. There was a
reduction in levels of both proteins suggesting that the changes in Cten levels following Kras knockdown were not due to altered degradation.
Controls consisting of DMSO carrier alone had no affect on protein levels (data not shown).
doi:10.1371/journal.pone.0020919.g003
Cten and Kras
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Kras-/GFP-
Cten) and compared with cells co-transfected with Kras specific
siRNA and GFP expressing empty vector controls (SW620
Kras-/evc).
Experimental controls were cells co-transfected with scrambled
siRNA duplexes and GFP empty vector (SW620
ssc/evc) creating a
condition in which neither Kras nor Cten were altered (Figure 4a).
Although creation of the appropriate conditions was confirmed by
Western blotting, for the purposes of cell motility studies, it was
necessary to confirm a high efficiency of transfection of the GFP-
Cten expression vector into the cells. Flow cytometry demonstrated
that a transfection efficiency of 60% was achieved (Figure S3).
Knockdown of Kras with co-transfection of GFP empty vector
significantly reduced cell motility in transwell migration assay
(Figure 4b, SW620
ssc/evc versus SW620
Kras-/evc,p ,0.001). How-
ever, ectopic expression of GFP-Cten restored the cell motility
(SW620
Kras-/evc versus SW620
Kras-/GFP-Cten,p ,0.001). Cell
wounding assays using the same transfection protocol demon-
strated the same effect and validated the data (Figure 4c,
p,0.001). Thus the data show that the effect of Kras knockdown
on cell motility can be rescued by ectopic expression of Cten
thereby confirming the functional nature of the relationship
between Kras and Cten.
(e) Kras/Cten in pancreatic cancer
Our current data have shown that, in CRC, Kras appears to
regulate Cten and, through this, to regulate cell motility. In order
to test whether this was a colon-specific relationship or whether it
also occurred in other tumour types, the experiments were
repeated in cell lines derived from pancreatic cancers. This was
chosen as a model because pancreatic cancer has a high frequency
of KRAS mutation. Colo357 and PSN1 are both pancreatic cancer
cell lines which show high Cten expression and are reportedly
mutant for KRAS. Knockdown of Kras in both cell lines resulted in
down-regulation of Cten (Figure 5a) compared with scrambled
controls. A second siRNA duplex targeted to Kras was also tested
to preclude ‘‘off-target’’ effects and this also showed inhibition of
Cten expression (Figure 5b) . Functional studies to further test this
relationship were performed in PSN1 and once again co-
transfections were used to create the conditions whereby Kras
alone was knocked down (PSN1
Kras-/evc), Kras was knocked and
Cten restored (PSN1
Kras-/GFP-Cten) and neither was altered
(PSN1
ssc/evc). The data paralleled those in the CRC cell lines
and Kras knockdown was demonstrated to inhibit cell motility
(PSN1
Kras-/evc versus PSN1
ssc/evc,p ,0.001) whilst this could be
rescued by restoration of Cten expression (PSN1
Kras-/evc versus
PSN1
Kras-/GFP-Cten,p ,0.001, Figure 5c).
Discussion
Our previous study, in which we had forcibly expressed Cten
protein in cell lines which were negative for Cten expression,
suggested that Cten is involved in the regulation of cell migration
and invasion. Although this was demonstrated in two different cell
lines, we felt it necessary to confirm these observations using a
different technique. Knockdown of Cten in the CRC cell line
Figure 4. The relationship between Kras and Cten in the colon. (a) SW620 cells were transfected with Kras-specific siRNA and cells were either
co-transfected with GFP-Cten expression vector (SW620
Kras-/GFP-Cten) to restore Cten or GFP empty vector (SW620
Kras-/evc). Control cells were co-
transfected with scrambled controls siRNA duplexes and GFP empty vector (SW620
ssc/evc). The ectopically expressed Cten has a larger size due to the
GFP tag. (b) Transwell migration assays and (c) wounding assays showing that in SW620, knockdown of Kras inhibited cell motility which was rescued
by the ectopic expression of Cten. (EVC=empty vector control, GFP=Green Fluorescent Protein, SSC=sequence scrambled controls).
doi:10.1371/journal.pone.0020919.g004
Cten and Kras
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and caused up-regulation of E-cadherin thereby validating our
previous data and firmly establishing the role of Cten in regulating
cell motility.
Little is known of the mechanism of Cten regulation and, in this
study, we have found an association between high Cten expression
and KRAS/BRAF mutation in CRC cell lines. We have
demonstrated Cten is a true target of Kras signalling since
(i) knockdown of Kras results in down-regulation of Cten in two
cell lines which are mutant for KRAS and (ii) knockdown of Kras in
a cell line mutant for BRAF has no effect on Cten expression whilst
knockdown of Braf in this cell line does result in down-regulation
of Cten. Furthermore, quantification of Cten mRNA and use of
proteasomal inhibitors to prevent protein degradation suggested
that the level of control lay at Cten transcription.
Taking cognizance of the fact that there are a large number of
reported targets of Kras and it is unlikely that they will all be
functionally relevant [20], we have shown that the relationship
between Kras and Cten is functionally important since inhibition
of motility following Kras knockdown can be rescued by ectopic
expression of Cten. Furthermore, we have demonstrated that the
interaction between Kras and Cten is similar in pancreatic cancer
suggesting that this is a generic relationship which is not limited to
CRC.
This is the first report of Cten as a target of Kras signalling
although it is clear that there are other mechanisms controlling
Cten expression since we have identified occasional cell lines
mutant for KRAS which show low levels of Cten. Conversely, there
are cell lines which are wild type for KRAS/BRAF but which have
high levels of Cten. Recently Stat3 has been reported as a
modulator of Cten expression [21] and may represent an alternate
pathway for Cten regulation. Currently, we can speculate that
when Cten expression is elevated in a tumour with KRAS/BRAF
mutation, the association is likely to be causal.
Our data suggest that a Kras-Cten signalling pathway exists
which regulates cell motility. Taken together with studies in breast
cancer showing that EGFR signalling can regulate Cten
expression, a wider EGFR-Kras-Cten signalling pathway can be
inferred. Circumstantial support for this comes from studies
showing high levels of Cten expression in lung cancer [10];
tumours in this organ have a high frequency of disrupted EGFR/
Kras signalling due to either Kras or EGFR mutation. However,
Figure 5. The relationship between Kras and Cten in the pancreas. Experiments to test the relationship between Kras and Cten were
repeated in pancreatic cancer cell lines. (a) shows that when Kras was knocked down in Colo357 and PSN1, this caused down-regulation of Cten
(Colo357
Kras- versus Colo357
ssc-, PSN-1
Kras- versus PSN-1
ssc-). In order to obviate any confounding off-target effects, a second anti-Kras siRNA duplex
was used. (b) shows that the second Kras specific duplex also resulted in reduction in both Kras levels and Cten levels. (c) shows that, as observed in
the colon, in pancreatic cell lines, knockdown of Kras inhibited motility (PSN-1
Kras-/evc versus PSN-1
ssc/evc) and this could rescued by transfection of
GFP-tagged Cten (PSN-1
Kras-/evc versus PSN-1
Kras-/GFP-Cten). (d) is confirmation of the changes induced by the gene knockdown/forced expression in
the rescue experiments.
doi:10.1371/journal.pone.0020919.g005
Cten and Kras
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20919Kras acts as a secondary messenger for a large number of
Receptor Tyrosine Kinases (RTKs) in addition to EGFR and
many of these, on ligand binding, can stimulate cell motility [22].
It is possible, albeit speculative at this stage, that Cten may
represent a mechanistic link between many different RTKs and
remodelling focal adhesions which will likely be an essential part of
the process of inducing cell motility. Furthermore, our demon-
stration that E-cadherin levels are modulated by Cten provides a
potential means of cross-talk and co-ordination between integrin
and cadherin mediated cell adhesion.
As well as raising some fascinating questions about the role of
Cten in regulating cell motility, our data also have some therapeutic
implications. The use of biologics targeted to the EGFR can have a
dramatic effect on CRC resulting in marked reduction in tumour
sizeand clinical down-staging[23]. However, as would be expected,
tumours containing KRAS/BRAF mutation are refractory to the
therapeutic effects of anti-EGFR antibodies. If future studies
confirm that Cten is a part of the EGFR-Kras signalling pathway,
itmayrepresenta new therapeutic optionforthe significantnumber
of CRCs (approximately 60%) containing KRAS/BRAF mutation
and therefore ineligible for anti-EGFR therapy.
Supporting Information
Figure S1 Validation of the functional activity of DN-TCF4 was
shown by flow cytometry. The expression of cell surface CD24 was
tested following transfection into SW620 of either an expression
construct expressing DN-TCF4 (SW620
DN-TCF4) or empty vector
(SW620
evc). Gating levels were ascertained using an isotype PE-
labelled control antibody and it was shown that DN-TCF4
resulted in a 53% reduction in cells expressing CD24.
(TIF)
Figure S2 To confirm that the proteasomal inhibitor (PI) was
effective, RKO cells were incubated either with the inhibitor or
with DMSO and levels of b-catenin were quantified. Exposure to
the proteasomal inhibitor resulted in inhibition of b-catenin
degradation making it detectable by Western blotting.
(TIF)
Figure S3 High efficiency of transfection of GFP-Cten into
SW620 was confirmed by flow cytometry. To ensure that exposure
to lipofectamine (the transfection reagent) did not influence
fluorescence, control cells were transfected with a scrambled
siRNA control. In comparison with control cells, there was
approximately 60% transfection efficiency.
(TIF)
Table S1 This is a table of the cell lines showing fold change in
CTEN message expression compared with the mean value for
normal mucosa (as previously described in Albasri et al. J Pathol
2009; 218, 57–65). The column alongside indicates whether there
is a mutation in the hotspots of KRAS or BRAF.
(DOC)
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